Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Prospective, Observational Study of Patients With Chronic Inflammatory Diseases, to Assess 12-months Persistence Drivers After Switching to an Adalimumab Biosimilar, Idacio®, in a Real World Setting

NCT05190484 is registered in ClinicalTrials.gov with Fresenius Kabi as lead sponsor.

NCT NCT05190484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05190484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Prospective, Observational Study of Patients With Chronic Inflammatory Diseases, to Assess 12-months Persistence Drivers After Switching to an Adalimumab Biosimilar, Idacio®, in a Real World Setting
Lead sponsor
Fresenius Kabi
Phase
Observational
Overall status
Unknown status
Start date
April 30, 2022
Completion date
April 30, 2024
Enrollment
1,050 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, crohn disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis